NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Significant Decline in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 555,312 shares, a decrease of 18.5% from the December 15th total of 681,153 shares. Based on an average daily volume of 293,318 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 293,318 shares, the short-interest ratio is presently 1.9 days.

NeuroSense Therapeutics Stock Performance

NeuroSense Therapeutics stock traded down $0.04 during mid-day trading on Monday, hitting $0.95. The company’s stock had a trading volume of 103,757 shares, compared to its average volume of 256,001. The company has a 50 day moving average of $0.97 and a 200-day moving average of $1.22. NeuroSense Therapeutics has a one year low of $0.68 and a one year high of $2.60.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics during the 3rd quarter valued at about $26,000. Squarepoint Ops LLC increased its position in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NRSN. Zacks Research raised NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Noble Financial raised shares of NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.